NKGen Biotech, Inc. (NKGN)

OTCMKTS · Delayed Price · Currency is USD

0.3300

+0.0190 (6.11%)

Jun 6, 2025, 2:21 PM EDT

NKGen Biotech Employees

NKGen Biotech had 63 employees as of December 31, 2023.

Employees

63

Change

n/a

Growth

n/a

Revenue / Employee

n/a

Profits / Employee

-$769,492

Market Cap

25.42M

Employees Chart

Employees History

Date	Employees	Change	Growth
Dec 31, 2023	63	-	-

Related Stocks

Company Name	Employees
Endo Inc.	3,116
Tian'an Technology Group	8
Elite Pharmaceuticals	64
Glass House Brands	374
CytoDyn	9
Northwest Biotherapeutics	25
American Oncology Network	1,914
Silence Therapeutics	116

Employee Rankings

NKGen Biotech News

4 weeks ago - NKGen Biotech Chairman & CEO Paul Y. Song, M.D. - GlobeNewsWire
7 weeks ago - NKGen Biotech To Present on the Use of Troculeucel for Alzheimer's and Parkinson's Disease at the 7th China International Biotechnology Conference & Exhibition - Benzinga
7 weeks ago - NKGen Biotech To Present on the Use of Troculeucel for Alzheimer's and Parkinson's Disease at the 7th China International Biotechnology Conference & Exhibition - GlobeNewsWire
2 months ago - NKGen Biotech Presents Data from Phase 1/2a Clinical Trial of Troculeucel in Moderate Alzheimer's Disease at the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD™ 2025) - GlobeNewsWire
2 months ago - NKGen Biotech To Present Updated Troculeucel Data at the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD™ 2025) - GlobeNewsWire
3 months ago - NKGen Biotech, Inc. to Transition from the Nasdaq Global Market to OTC Markets; Reverse Stock Split will not be Implemented - GlobeNewsWire
3 months ago - NKGen Biotech Announces Administration of First Dose of Troculeucel to Stroke Patient Under FDA-Cleared Compassionate Use Program - GlobeNewsWire
3 months ago - NKGen Biotech Announces Administration of First Dose of Troculeucel to Frontotemporal Dementia Patient Under FDA-Cleared Compassionate Use Program - GlobeNewsWire